(Unaudited data)
Development of business in the third quarter (variation at current rate)
| thousands of euros | 1 st Quarter | 2 nd Quarter | 3 rd Quarter | ||||||
| 2014 | 2015 | Var. 15/14 | 2014 | 2015 | Var. 15/14 | 2014 | 2015 | Var. 15/14 | |
| France | 82,749 | 89,584 | + 8.3% | 74,269 | 76,864 | + 3.5% | 92,466 | 97,767 | + 5.7% |
| Europe (excluding France) | 39,967 | 40,657 | + 1.7% | 33,570 | 29,943 | - 10.8% | 62,758 | 50,614 | - 19.4% |
| North America | 12,662 | 17,193 | + 35.8% | 10,625 | 12,894 | + 21.4% | 13,109 | 16,055 | + 22.5% |
| Other countries | 4,831 | 4,622 | - 4.3% | 2,943 | 3,816 | + 29.7% | 3,779 | 3,594 | - 4.9% |
| Group total | 140,209 | 152,056 | + 8.4% | 121,407 | 123,517 | + 1.7% | 172,112 | 168,030 | - 2.4% |
| thousands of euros | 1 st Quarter | 2 nd Quarter | 3 rd Quarter | ||||||
| 2014 | 2015 | Var. 15/14 | 2014 | 2015 | Var. 15/14 | 2014 | 2015 | Var. 15/14 | |
| Non-proprietary Homeopathic Medicines | 77,919 | 79,191 | + 1.6% | 73,072 | 74,354 | + 1.8% | 72,957 | 73,677 | + 1.0% |
| OTC Specialties | 62,196 | 72,880 | +17.2% | 48,058 | 49,030 | + 2.0% | 99,025 | 94,328 | - 4.7% |
| Other | 94 | -15 | - | 277 | 133 | - 52.0% | 130 | 25 | - 80.8% |
| Group total | 140,209 | 152,056 | + 8.4% | 121,407 | 123,517 | + 1.7% | 172,112 | 168,030 | - 2.4% |
Cumulative activity as of the end of september 2015
| thousands of euros | 2014 | 2015 | Variation at current exchange rates | Variation at constant exchange rates |
| France | 249,484 | 264,215 | + 5.9% | + 5.9% |
| Europe (excluding France) | 136,295 | 121,214 | - 11.1% | - 7.1% |
| North America | 36,396 | 46,142 | + 26.8% | + 7.1% |
| Other countries | 11,553 | 12,032 | + 4.1% | + 6.7% |
| Group total | 433,728 | 443,603 | + 2.3% | + 1.9% |
| thousands of euros | 2014 | 2015 | Variation at current exchange rates | Variation at constant exchange rates |
| Non-proprietary Homeopathic Medicines | 223,948 | 227,222 | + 1.5% | + 0.5% |
| OTC Specialties | 209,279 | 216,238 | + 3.3% | + 3.6% |
| Other | 501 | 143 | - 71.5% | - 48.9% |
| Group total | 433,728 | 443,603 | + 2.3% | + 1.9% |
Highlights of the third quarter
- Sales revenue in the 3 rd quarter of 2015 are decreasing by 2.4% in comparison to 2014 (-1% at constant rate) with a revenue growth in France and the USA, but in decline mainly in Russia and to a lesser extent in Italy and Poland.
- Boiron announced its plan to locate its future logistic platform in the town of Les Olmes, near Tarare in the West of Lyon. Meanwhile, construction work for the site extension of Messimy have begun.
- Boiron put on the French market a new cough syrup, Stodaline ®.
Outlook
- Boiron continues its involvement in the development of homeopathy in the world.
- Given the development of the activity at the end of September 2015 and the unpredictability of seasonal pathology of the last quarter, the operational income may not reach the same level as in 2014.
Our next update: January 21, 2016 at market close, publication of the sales revenue for the year 2015.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com
Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-41752-BOI-161015-CA-T3-15-GB.pdf
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer